why choose us

First received: December 20, 2022

Clinical Trial: Pyrimethamine as an Inhibitor of NRF2 in HPV-negative Locally Advanced Head and Neck Squamous Cell Carcinoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Head and Neck Cancer

Study Type: INTERVENTIONAL


Official Title: Early Phase I Window of Opportunity Biomarker and Safety Trial to Test Pyrimethamine as an Inhibitor of NRF2 in HPV-negative, Locally Advanced Head and Neck Squamous Cell Carcinoma

Brief Summary: NRF2 activation, observed in up to 40% of head and neck squamous cell carcinoma (HNSCC) tumors, plays a critical role in tumor progression, metastasis, and radiation therapy resistance.The investigators have recently discovered that pyrimethamine (PYR) and its analogs have an inhibitory effect on NRF2 activity in vitro and in mouse models via inhibition of dihydrofolate reductase (DHFR).Pyrimethamine is an established drug that has been used for decades for treatment of protozoan infections and malaria.A growing…

Read more